Insmed reported $99.66M in Current Liabilities for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Acelrx Pharmaceuticals ACRX:US $ 15.19M 0.36M
Alexion Pharmaceuticals ALXN:US $ 1426.2M 198.5M
Alimera Sciences ALIM:US $ 10.31M 0.9M
Arena Pharmaceuticals ARNA:US $ 64.84M 17.33M
Biomarin Pharmaceutical BMRN:US $ 443.34M 13.31M
Cytokinetics CYTK:US $ 61.77M 25.84M
Dynavax Technologies DVAX:US $ 204.64M 95.22M
Flexion Therapeutics FLXN:US $ 39.93M 18.05M
Gilead Sciences GILD:US $ 10214M 509M
Heron Therapeutics HRTX:US $ 82.14M 18.77M
Insmed INSM:US $ 99.66M 18.26M
Mirati Therapeutics MRTX:US $ 180.87M 103.76M
Novartis NVS:US $ 29633M 527M
Regeneron Pharmaceuticals REGN:US $ 3732.4M 514.6M
Sarepta Therapeutics SRPT:US $ 425.02M 60.29M
Seattle Genetics SGEN:US $ 433.83M 44.22M
Ultragenyx Pharmaceutical RARE:US $ 127.07M 0.02M
Vertex Pharmaceuticals VRTX:US $ 1836.45M 107.6M